Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
7.48
+0.48 (6.86%)
At close: Apr 17, 2026, 4:00 PM EDT
7.50
+0.02 (0.27%)
After-hours: Apr 17, 2026, 5:30 PM EDT

Relmada Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-57.39-79.98-98.79-157.04-125.75
Depreciation & Amortization
----0
Stock-Based Compensation
15.8730.1943.8144.1940.49
Other Adjustments
-0.32-0.380.24-1.551.25
Change in Receivables
--0.51-0.51-
Changes in Accounts Payable
-2.560.62-1.760.422.85
Changes in Accrued Expenses
-1.3-2.531.483.34-0.39
Changes in Other Operating Activities
-0.090.322.847.35-10.32
Operating Cash Flow
-45.79-51.76-51.66-103.8-91.87
Purchases of Investments
-83.83-12.08-90.46-47.29-222.98
Proceeds from Sale of Investments
35.6963.64140.9267.03168.86
Investing Cash Flow
-48.1451.5650.4519.73-54.12
Issuance of Common Stock
93.640.25-45.07187.94
Net Common Stock Issued (Repurchased)
93.640.25-45.07187.94
Other Financing Activities
-0.07-0.29-0.1-0.05-
Financing Cash Flow
93.56-0.04-0.145.02187.94
Net Cash Flow
-0.36-0.23-1.3-39.0541.95
Free Cash Flow
-45.79-51.76-51.66-103.8-91.87
Free Cash Flow Per Share
-1.16-1.72-1.72-3.50-5.23
Levered Free Cash Flow
-61.33-81.56-96.22-145.94-133.62
Unlevered Free Cash Flow
-63.05-85.47-101.13-150.14-133.57
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q